Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Burgstaller, S; Buxhofer-Ausch, V; Sliwa, T; Beham-Schmid, C; Gastl, G; Geissler, K; Melchardt, T; Krauth, M; Krippl, P; Petzer, A; Rumpold, H; Wölfler, A; Gisslinger, H.
Austrian recommendations for the management of polycythemia vera.
Wien Klin Wochenschr. 2018; 130(17-18):535-542 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Beham-Schmid Christine
Krippl Peter
Wölfler Albert

Dimensions Citations:

Plum Analytics:
Polycythemia vera (PV) is a clonal disease arising from hematopoietic stem cells. Erythrocytosis is the hallmark of the disease but leukocytosis, thrombocytosis and splenomegaly may also be present. Thromboembolic complications occur in about 20% of patients. Circulatory disturbances as well as pruritus represent frequent symptoms of the disease. Mutations in the JAK2 gene are present in 95% of patients in exon 14 (V617F) and in 3% in exon 12. The main goal of the treatment for patients with PV is the prevention of thromboembolic events, transformation to myelofibrosis and acute myeloid leukemia. Interferon alpha and hydroxyurea are used as first-line treatment for high risk patients. For patients unresponsive to first-line therapy ruxolitinib is available.
Find related publications in this database (using NLM MeSH Indexing)
Female -
Humans -
Janus Kinase 2 - genetics
Male -
Polycythemia Vera - diagnosis
Polycythemia Vera - drug therapy
Polycythemia Vera - genetics
Primary Myelofibrosis -
Thrombocytosis - prevention & control

Find related publications in this database (Keywords)
Polycythemia vera
Management recommendations
Risk stratification
© Med Uni Graz Impressum